Response to: 'The GRAPPA-OMERACT initiative to standardise outcomes in Psoriatic Arthritis clinical trials and longitudinal observational studies' by Tillet et al

Ann Rheum Dis. 2018 May;77(5):e24. doi: 10.1136/annrheumdis-2017-212012. Epub 2017 Aug 16.

Sofia Ramiro¹, Josef S Smolen^{2

3}, Robert B M Landewé^{4

5}, Désirée van der Heijde¹, Laure Gossec^{6

7}

¹ Department of Rheumatology, Leiden University Medical Center, Leiden, The Netherlands.
² Division of Rheumatology, Department of Medicine III, Medical University of Vienna, Vienna, Austria.
³ Department of Medicine, Hietzing Hospital, Vienna, Austria.
⁴ Department of Clinical Immunology and Rheumatology, Amsterdam Rheumatology Center, Amsterdam, The Netherlands.
⁵ Zuyderland Hospital, Heerlen, The Netherlands.
⁶ UPMC Univ Paris 06, Institut Pierre Louis d'Epidémiologie et de Santé Publique, GRC-UPMC 08 (EEMOIS), Sorbonne Universités, Paris, France.
⁷ Department of Rheumatology, AP-HP, Pitié Salpêtrière Hospital, Paris, France.

No abstract available

Keywords: disease activity; psoriatic arthritis; treatment.

Publication types